Evidence map›Paper›PMID 40406145›Full record

ArticleFrontiers in immunology2025

Case Report: Endocrine, immune and disease dynamics in a patient with rheumatoid arthritis during flare and medication change.

Lennart Seizer, Johanna M Gostner, Christoph Garbers, Melina Licht, Sebastian Sager, Andreas Brandl, Christian Schubert

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lennart SeizerDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Tübingen, Tübingen, Germany.
Johanna M GostnerInstitute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Christoph GarbersInstitute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
Melina LichtFaculty of Mathematics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Sebastian SagerFaculty of Mathematics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Andreas BrandlConservative and Rehabilitative Orthopedics, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany.
Christian SchubertDepartment of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease of mostly unknown etiology and pathophysiology. In this integrative single-case study on a patient with RA, we had the unique opportunity to closely monitor the individual dynamics of endocrine, immune and disease variables during a naturally occurring flare-up and subsequent medication change. Methods: The 59-year-old female RA patient collected her entire urine over 30 days in 12-h intervals (60 consecutive measurements in total). Subsequently, cortisol, interleukin-6 (IL-6), orosomucoid-2 (ORM-2), neopterin and creatinine levels were determined in the urine samples. Further, each morning and evening, the patient completed the DIARI, a set of questionnaires on variables such as perceived pain, perceived RA disease activity and emotional states. Once a week, the patient was interviewed online and had an appointment with her rheumatologist, in which several indices of RA disease activity were determined: SDAI, CDAI and DAS28. From these data various time series were constructed for statistical analysis. Results: RA disease state increased from low to high activity during the first 12 study days. Thereupon, the medication was changed, which proved effective in reducing RA disease activity. However, the levels of urinary neopterin, urinary IL-6 and urinary ORM-2 did not show any response, neither to the increasing disease activity nor the medication change. The patient's daily reports on pain, RA disease activity, emotional states and body temperature, however, mirrored the course of the rheumatologic indices. Conclusion: This integrative single-case study clearly demonstrated the importance of process analysis for the evaluation of therapeutic measures in RA. In the studied patient, urinary levels of neopterin, IL-6 and ORM-2 were not found to be appropriate biomarkers of short-term fluctuations in RA disease activity. Instead, the results reported by the patient proved to be a useful tool for ambulatory and longitudinal monitoring of RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiomarkersFemaleHumansHydrocortisoneInterleukin-6Middle AgedNeopterinSymptom Flare UpAntirheumatic AgentsBiomarkersHydrocortisoneInterleukin-6Neopterincortisolflareintegrative single-case studyinterleukin-6neopterinorosomucoid-2rheumatoid arthritistime series

Identifiers

PMID40406145
PMCPMC12094934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.